RT Journal Article
T1 Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done.
A1 Llerena, Susana
A1 Cabezas, Joaquín
A1 Cuadrado, Antonio
A1 Manuel Olmos, José
A1 González, Marta
A1 García, Federico
A1 Cobo, Carmen
A1 Crespo, Javier
K1 Genotype 3
K1 Grazoprevir + Elbasvir
K1 Hepatitis C virus
K1 Sofosbuvir
K1 Treatment failure
AB Nowadays, the retreatment of patients with Hepatitis C virus (HCV) genotype 3 (GT3) especially cirrhotic, who have already been treated with regimens containing a NS5A inhibitor represents a challenge. Use a novel retreatment option for patients with a difficult approach. We present three case reports of retreatment with a new combination of Direct-acting antivirals (DAAs), Sofosbuvir, Elbasvir/Grazoprevir in patients with GT3 with a previous failure with Sofosbuvir/Ledipasvir. All the cases achieved sustained virologic response (SVR) at week +12 without adverse effects. In our experience, this combo may represent an effective and safe option for these patients.
SN 1665-2681
YR 2019
FD 2019
LK http://hdl.handle.net/10668/13999
UL http://hdl.handle.net/10668/13999
LA en
DS RISalud
RD Apr 4, 2025